Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

The company's intent here is pretty clear:
They think that the share price will spike once the abstracts are released and presented so that they immediately run an offering. It all comes down to one question: Is data strong enough to warrant a spike? We shall see within two weeks. So far, the company has had a history of miscalculating the effects and the significance of the clinical data they have released. Last two times, the management tried to pump the share price before the secondaries by issuing fluff PRs, rehashing old data, and the markets did not buy that. This time it looks like there's some strong force behind this cycle -- we see a surprisingly strong support for the share price. It looks like it's more than the AACR presentations -- it might be something to do with an upcoming deal. Thus, I'm counting not just on AACR data, but something more important after this conference. Deal or data -- nothing else matta...